NeoGenomics (NEO) Issues FY18 Earnings Guidance

NeoGenomics (NASDAQ:NEO) issued an update on its FY18 earnings guidance on Wednesday morning. The company provided EPS guidance of $0.15-0.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.21.

NeoGenomics (NASDAQ:NEO) traded up $0.72 during mid-day trading on Thursday, reaching $8.08. The company had a trading volume of 1,518,900 shares, compared to its average volume of 429,590. NeoGenomics has a fifty-two week low of $7.08 and a fifty-two week high of $11.63. The firm has a market capitalization of $591.81, a P/E ratio of -23.09, a PEG ratio of 2.97 and a beta of 0.57. The company has a current ratio of 2.14, a quick ratio of 1.99 and a debt-to-equity ratio of 0.57.

NeoGenomics (NASDAQ:NEO) last released its earnings results on Wednesday, February 21st. The medical research company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.01. NeoGenomics had a positive return on equity of 3.97% and a negative net margin of 4.78%. The business had revenue of $67.79 million for the quarter, compared to the consensus estimate of $66.32 million. During the same period last year, the business earned $0.05 earnings per share. The firm’s revenue for the quarter was up 12.1% compared to the same quarter last year. research analysts predict that NeoGenomics will post 0.04 EPS for the current fiscal year.

NEO has been the topic of a number of recent research reports. Royal Bank of Canada set a $23.00 target price on NeoGenomics and gave the stock an outperform rating in a research report on Wednesday, January 3rd. BidaskClub downgraded NeoGenomics from a buy rating to a hold rating in a research report on Thursday, December 21st. Scotiabank set a $22.00 target price on NeoGenomics and gave the stock an outperform rating in a research report on Wednesday, January 3rd. CIBC set a $19.00 target price on NeoGenomics and gave the stock a neutral rating in a research report on Wednesday, January 3rd. Finally, Janney Montgomery Scott reissued a buy rating on shares of NeoGenomics in a research report on Thursday, October 26th. Five research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $15.83.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Week Herald and is the sole property of of Week Herald. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at

About NeoGenomics

NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with's FREE daily email newsletter.

Leave a Reply